The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma

Gouji Toyokawa, Kenichi Taguchi, Makoto Edagawa, Shinichiro Shimamatsu, Ryo Toyozawa, Kaname Nosaki, Fumihiko Hirai, Masafumi Yamaguchi, Mototsugu Shimokawa, Takashi Seto, Mitsuhiro Takenoyama, Ryuji Hamamoto, Kenji Sugio, Yukito Ichinose

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.

Original languageEnglish
Pages (from-to)4841-4846
Number of pages6
JournalAnticancer research
Volume36
Issue number9
DOIs
Publication statusPublished - Sep 2016

Fingerprint

Lung Neoplasms
Survival
Adenocarcinoma of lung
Adenocarcinoma
Multivariate Analysis
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Toyokawa, G., Taguchi, K., Edagawa, M., Shimamatsu, S., Toyozawa, R., Nosaki, K., ... Ichinose, Y. (2016). The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma. Anticancer research, 36(9), 4841-4846. https://doi.org/10.21873/anticanres.11046

The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma. / Toyokawa, Gouji; Taguchi, Kenichi; Edagawa, Makoto; Shimamatsu, Shinichiro; Toyozawa, Ryo; Nosaki, Kaname; Hirai, Fumihiko; Yamaguchi, Masafumi; Shimokawa, Mototsugu; Seto, Takashi; Takenoyama, Mitsuhiro; Hamamoto, Ryuji; Sugio, Kenji; Ichinose, Yukito.

In: Anticancer research, Vol. 36, No. 9, 09.2016, p. 4841-4846.

Research output: Contribution to journalArticle

Toyokawa, G, Taguchi, K, Edagawa, M, Shimamatsu, S, Toyozawa, R, Nosaki, K, Hirai, F, Yamaguchi, M, Shimokawa, M, Seto, T, Takenoyama, M, Hamamoto, R, Sugio, K & Ichinose, Y 2016, 'The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma', Anticancer research, vol. 36, no. 9, pp. 4841-4846. https://doi.org/10.21873/anticanres.11046
Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K et al. The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma. Anticancer research. 2016 Sep;36(9):4841-4846. https://doi.org/10.21873/anticanres.11046
Toyokawa, Gouji ; Taguchi, Kenichi ; Edagawa, Makoto ; Shimamatsu, Shinichiro ; Toyozawa, Ryo ; Nosaki, Kaname ; Hirai, Fumihiko ; Yamaguchi, Masafumi ; Shimokawa, Mototsugu ; Seto, Takashi ; Takenoyama, Mitsuhiro ; Hamamoto, Ryuji ; Sugio, Kenji ; Ichinose, Yukito. / The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma. In: Anticancer research. 2016 ; Vol. 36, No. 9. pp. 4841-4846.
@article{37b112f500d944b794a9b4dfcc8a55c6,
title = "The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma",
abstract = "Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64{\%}) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7{\%} vs. 92.6{\%}; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.",
author = "Gouji Toyokawa and Kenichi Taguchi and Makoto Edagawa and Shinichiro Shimamatsu and Ryo Toyozawa and Kaname Nosaki and Fumihiko Hirai and Masafumi Yamaguchi and Mototsugu Shimokawa and Takashi Seto and Mitsuhiro Takenoyama and Ryuji Hamamoto and Kenji Sugio and Yukito Ichinose",
year = "2016",
month = "9",
doi = "10.21873/anticanres.11046",
language = "English",
volume = "36",
pages = "4841--4846",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma

AU - Toyokawa, Gouji

AU - Taguchi, Kenichi

AU - Edagawa, Makoto

AU - Shimamatsu, Shinichiro

AU - Toyozawa, Ryo

AU - Nosaki, Kaname

AU - Hirai, Fumihiko

AU - Yamaguchi, Masafumi

AU - Shimokawa, Mototsugu

AU - Seto, Takashi

AU - Takenoyama, Mitsuhiro

AU - Hamamoto, Ryuji

AU - Sugio, Kenji

AU - Ichinose, Yukito

PY - 2016/9

Y1 - 2016/9

N2 - Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.

AB - Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84991698841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991698841&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11046

DO - 10.21873/anticanres.11046

M3 - Article

C2 - 27630338

AN - SCOPUS:84991698841

VL - 36

SP - 4841

EP - 4846

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -